Synaffix China California

New deal builds on encouraging preliminary clinical data from the Phase 1 study of the first antibody-drug conjugate (ADC) developed under the agreement signed in June 2021The expanded collaboration to provide Innovent with access to additional targets and further proprietary Synaffix linker-payloads for the development of additional innovative ADCs Synaffix will be eligible to receive an upfront fee plus potential milestone payments and royalties on commercial sales for each licensed targetView original content:https://www.prnewswire.co.uk/news-releases/innovent-biologics-and-synaffix-expand-adc-collaboration-following-positive-preliminary-clinical-signal-from-ongoing-phase-1-study-302008012.html